Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$39.74 USD
-0.25 (-0.63%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $39.76 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
RVMD 39.74 -0.25(-0.63%)
Will RVMD be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for RVMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RVMD
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
RVMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
Other News for RVMD
Tracking Baker Brothers Portfolio - Q1 2024 Update
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
Revolution Medicines: On Hold Pending A Lower Entry Point